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ABSTRACT
Cytosine-5 DNA methylation is a critical signal
de®ning heritable epigenetic states of transcription.
As aberrant methylation patterns often accompany
disease states, the ability to target cytosine methyl-
ation to preselected regions could prove valuable in
re-establishing proper gene regulation. We employ
the strategy of targeted gene methylation in yeast,
which has a naturally unmethylated genome, select-
ively directing de novo DNA methylation via the
fusion of C5 DNA methyltransferases to heterolo-
gous DNA-binding proteins. The zinc-®nger proteins
Zif268 and Zip53 can target DNA methylation by
M.CviPI or M.SssI 5±52 nt from single zinc-factor
binding sites. Modi®cation at speci®c GC (M.CviPI)
or CG (M.SssI) sites is enhanced as much as 20-fold
compared with strains expressing either the free
enzyme or a fusion protein with the zinc-®nger
protein moiety unable to bind to DNA. Interestingly,
methylation is also selectively targeted as far as
353 nt from the zinc-®nger protein binding sites,
possibly indicative of looping, nucleosomes or
higher-order chromatin structure. These data
demonstrate that methylation can be targeted in vivo
to a potentially broad range of sequences using
speci®cally engineered zinc-®nger proteins. Further-
more, the selective targeting of methylation by zinc-
®nger proteins demonstrates that binding of distinct
classes of factors can be monitored in living cells.
INTRODUCTION
Methylation of the C5 atom of cytosine in DNA (m5C) plays
an important role in establishing correct patterns of gene
expression in vertebrates, usually through repression of
transcription. Mechanistically, one way DNA methylation
can lead to transcriptional silencing is by decreasing the
binding af®nity of a transcriptional activator for its site (1).
The introduction of m5C at sites adjacent to a factor binding
site can also interfere with its binding (2). Perhaps more
importantly, symmetrical methylation of CpG sequences (CG)
serves as a signal for the recruitment of a family of methyl-
CpG binding domain (MBD) proteins, such as MeCP2 and
MBD2 (3). In turn, MBDs, either by themselves or as
components of complexes, are known to recruit a variety of
co-repressors, such as histone deacetylases (4±7), histone H3
lysine-9 methyltransferases (8) and heterochromatin coating
factors like HP1 (9), which can function to establish a local,
repressed region of chromatin (10±15). This silencing
mechanism is also conserved in plants, as the DNA
chromomethyltransferase CMT3, which methylates CNG
residues, interacts with HP1 to facilitate heterochromatin
formation (8).
While regions of m5C are often associated with hypo-
acetylation of histones H3 and/or H4 and altered chromatin
structure (10±15), recent evidence suggests DNA methylation-
and histone deacetylase-independent modes of silencing. First,
trichostatin A, a speci®c inhibitor of histone deacetylation,
fails to reactivate transcription from densely methylated DNA
(2,11,12,15±17). Additionally, mbd2-null mice are viable and
fertile (18) and Mecp2-null mice only display neurological
abnormalities (19), questioning their global role in m5C-
mediated silencing and cellular differentiation. Moreover,
puri®ed MeCP2 itself compacts reconstituted chromatin in the
absence of DNA methylation (20).
Although the mechanisms are not yet fully understood,
there is a strong correlation between promoter methylation and
gene silencing (1,21±23). Moreover, once a methylation state
is established, it is maintained heritably after many gener-
ations of replication (24) by the maintenance DNA methyl-
transferase (DMTase), Dnmt1 (25). An exception includes
enhancer sequences that can be passively demethylated on
replication and subsequent blockage of DMTase access by
factor binding (26±30). However, this enhancer-speci®c loss
of DNA methylation does not lead to derepression (26).
Proper regulation of gene expression is essential for normal
cellular functions and the avoidance of disease states. DNA
methylation, which occurs almost exclusively at CG dinucle-
otides in non-diseased cells, is localized to precise regions of
the genome, usually in transposons and retroviral elements
(25). In contrast, CG sites in euchromatic regions, most
notably when concentrated in CpG islands, are generally
unmethylated and are correlated with transcriptional activity.
However, in cancer and other diseases, patterns of DNA
methylation are frequently aberrant. For instance, the DNA in
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tumor cells is generally hypomethylated relative to that in
normal cells (31), which may lead to genomic instability (23).
In contrast, a number of tumor-suppressor genes, including
BRCA1 and retinoblastoma (Rb), become hypermethylated
and transcriptionally inactive (32). The presence of a single
methylated CG site in a gene's promoter is suf®cient to repress
its activation (21), although higher m5C density increases the
probability of establishing gene repression (14,33±36). Thus,
DNA methylation can be critical in de®ning the expression
state of a gene.
Therefore, directing DNA methylation to improperly regu-
lated loci could be used to re-establish proper gene expression
through silencing. Previously, targeting of m5C has been
demonstrated in vitro (37,38), however, selective enrichment
of m5C was not observed in vivo (38). Recently, in yeast, using
the dinucleotide-speci®city DMTase M.CviPI (39) fused to
the basic helix±loop±helix activator Pho4, we demonstrated
speci®c targeting of cytosine methylation to promoters
containing Pho4 binding sites [targeted gene methylation
(TAGM)] (40). Methylation was ef®ciently targeted to GC
sites in nucleosomes that were disrupted on promoter
activation, as well as to histone-free regions.
In its present form, the TAGM strategy is limited to known
factors that bind to well characterized DNA-binding sites,
which are often present in multiple copies throughout the
genome. Therefore, we have investigated the ability of zinc-
®nger proteins, which, in principle, may be selected to
recognize one or a small subset of chromosomal regions (41),
to target m5C in living cells. Whereas preferential targeting of
4 bp speci®city MTases was not observed in vivo (38), we now
show that, in yeast, both M.CviPI (GC methylation) and
M.SssI (CG methylation) can be preferentially targeted by
zinc-®nger proteins to speci®c GC or CG sites neighboring
their cognate binding sites. The potential to direct m5C at ~20-
fold increased resolution to a broad range of desired DNA
sequences could lead to novel therapeutic approaches.
MATERIALS AND METHODS
Plasmids, yeast strains and growth conditions
All yeast strains used in this study were derived from the
S288C background strain YPH500DL (MATa ade2-101 ura3-
52 his3-D200 leu2-D1 trp1-D63 lys2-D1) (26). Zinc-®nger
coding sequences were PCR ampli®ed using the primers
MKO46, 5¢-gcactagttaggccagctgggccATGGCTGATATCGG-
ATCTGG-3¢, and MKO47, 5¢-gaataattcgAGCGCTTTCAA-
GGTCATGGTGGATCCTAGGCCACCTCCACTCC-3¢, and
cloned between S®I and AfeI restriction sites as in-frame
fusions to either M.CviPI or M.SssI in pMPK1. The fusion
proteins are expressed under the control of the GAL1 promoter
after integration at LYS2 as previously described (26). Each
N-terminal zinc-®nger protein is separated from the DMTase
by a G(SGGGG)2SGGGLGST (GS linker) peptide (37). As a
free DMTase control, mutated Zif268 (mut Zif), which
contains a single amino acid substitution (H58E) (42) that
ablates DNA binding, was constructed by overlap site-directed
mutagenesis using the primers MKO72, 5¢-cagtcgtagtgac-
gAgcttaccacccac-3¢, and MKO73, 5¢-gtgggtggtaagcTcgtcac-
tacgactg-3¢ (mutated residues in upper case).
Cells were pre-grown in yeast extract (Difco)/peptone
(Difco)/2% dextrose (YPD) medium and then washed and
resuspended at an OD600 of 0.5 in YP/2% galactose (YPG).
After resuspension in YPG, cells were incubated at 30°C for
16 h, or for the indicated times (Fig. 1C).
Bisul®te genomic sequencing
Total genomic DNA was rapidly isolated by the phenol/
chloroform lysis method (43) and analyzed by bisul®te
genomic sequencing (44,45) as previously modi®ed (26).
PCR ampli®cation from bisul®te-treated genomic DNA with
the indicated primer pairs was performed with Jumpstart Taq
DNA polymerase (Sigma) and the resulting products were
subjected to primer extension using a 32P-labeled oligonucle-
otide as described previously using ®nal concentrations of
5 mM dATP, dCTP and dTTP (dGTP omitted) as well as 50 mM
ddGTP (26) (Figs 1 and 2), or with dNTPs (A, C, T) and
ddGTP increased to 50 and 150 mM, respectively (Figs 3±5),
as recently reported (40). Product intensities were determined
by ImageQuaNT software (Molecular Dynamics) after sub-
tracting the local background average. Absolute frequencies of
cytosine methylation were obtained by dividing the intensity
of a given band by all summed product intensities in a given
lane, including the run-off product at the top of the gel
generated by primer extension on templates lacking cytosine
residues (i.e. templates not methylated in vivo). Oligo-
nucleotides used for PCR ampli®cation of bisul®te-treated
DNA are described in Table 1 using the original naming
conventions of Frommer et al. (44).
RESULTS
In vivo targeting of C5 DMTases near single, Zif268
binding sites
m5C has been selectively targeted in vitro by fusing C5
DMTases (M.HhaI, M.HpaII and M.SssI) to zinc-®nger DNA-
binding factors (37,38). However, attempts to use zinc-®nger
proteins as targeting entities in vivo have been unsuccessful
(38). As a ®rst step toward targeting DNA methylation in vivo
using zinc-®nger proteins, we tested whether we could
increase cytosine methylation levels neighboring zinc-®nger
protein binding sites (ZBS) in the genetically tractable
eukaryote, Saccharomyces cerevisiae. Yeast genomic DNA
does not contain detectable levels of endogenous methylated
residues (46) (Figs 4A, lane 4 and 5A and C, lane 5), enabling
unambiguous detection of de novo DNA methylation. Also,
low-level expression of C5 DMTases in yeast has no known
effects on gene expression or growth (26,27,47).
Since chromatin blocks access of DMTases to their target
sites (26,27,47±49), our efforts to target m5C in vivo focus on
the use of enzymes that methylate dinucleotide sites. This
substantially increases the probability (~20-fold) that DMTase
target sites located in accessible, histone-free regions will be
modi®ed. Either of two C5 DMTases, M.CviPI (GC speci®-
city) (39) or M.SssI (CG speci®city) (50), was tethered to the
archetypal zinc-®nger protein, Zif268 (51) and expressed as a
single-copy, integrated gene under the control of the
galactose-inducible GAL1 promoter. The DNA-binding factor
that is fused to the DMTase is designated the targeting factor.
As a control, we expressed either the untethered DMTase or a
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fusion protein in which the DNA-binding activity of Zif268
was severely impaired (42). Strains expressing these `free'
DMTase controls establish the level of non-targeted methyl-
ation due to enzyme site preferences and accessibility in
protein-free DNA and chromatin (26,27,47±49).
Endogenous yeast Zif268 binding sites (5¢-GCGTGGGCG-
3¢) were identi®ed by the PatMatch search engine (http://
www.yeastgenome.org/). We determined the relative methy-
lation frequencies at multiple GC (M.CviPI) and CG (M.SssI)
sites at the CAR1 locus containing a single, consensus binding
Figure 1. Targeting C5 DMTases near a single Zif268 site. (A) Determination of m5C levels targeted by Zif268±DMTase fusions. Genomic DNA isolated
from strains expressing wild-type Zif268±M.CviPI (Zif±M.CviPI, lane 2), Zif268±M.SssI (Zif±M.SssI, lane 3), or `free' DMTase controls, a mutated Zif268
fused to M.CviPI (mut Zif±M.CviPI, lane 1) or M.SssI by itself (lane 4), was analyzed by modi®ed bisul®te genomic sequencing (26) of CAR1 from +558 to
+159. Distances (bp) of a subset of sites from the proximal edge of the Zif268 ZBS (®lled bar; +438 to +446) are indicated at left and right of the gel. Sites
of non-targeted methylation (®lled circles). Sites 46 (M.CviPI strains) and 25 (M.SssI strains) (arrows) were chosen for normalization to enable lane-to-lane
comparisons [see (B)]. Each DMTase was preferentially targeted to several CG and GC sites (asterisks) by Zif binding as compared with its respective control
(compare lanes 1 with 2 and 3 with 4). For site 19, 41% (of all summed intensities) of the templates in the population are methylated. Lanes T, G and A (left)
contain sequencing reactions with ddATP, ddCTP and ddTTP, respectively. (B) Quantitative scans of the phosphoimage in (A). See (A) for de®nitions of sym-
bols. (C) Time course of targeting M.CviPI by Zif268. Expression of Zif±M.CviPI (lanes 1±6) and Zif±M.SssI (lanes 7±9) from the GAL1 promoter was initi-
ated by transferring cells from YPD (dextrose) to YPG (galactose) medium. Genomic DNA was isolated at the indicated times and analyzed as in (A).
Symbols are de®ned in (A). (D) Quanti®cation of preferential targeting of M.CviPI by Zif268. Ratios of m5C for the indicated sites (normalized to site 46) for
Zif±M.CviPI to mut Zif±M.CviPI are given (mean 6 standard error; n = 3). Similar values are obtained if the ratios for each site are normalized to other sites
of non-targeted methylation (A, ®lled circles) or calculated using absolute frequencies of methylation (see Materials and Methods).
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site for Zif268 by bisul®te genomic sequencing (see Materials
and Methods) (40). Speci®c binding by the Zif268 moiety of
each fusion protein is supported by protection of multiple CG
and GC sites against methylation at the Zif268 site in strains
expressing a wild-type Zif268 fusion as compared with its
respective free DMTase (Fig. 1A±C, compare lanes 1 with 2
and 3 with 4, ®lled bar). Ratios of m5C among several sites in a
given lane are similar, identifying sites at which non-targeted
methylation occurs (®lled circles), which enables normal-
ization for differences in methylation activity between strains.
By this criterion, the mut Zif±M.CviPI strain has ~2-fold more
methylation activity than cells expressing Zif±M.CviPI. The
reason for this activity difference is unclear. DNA methylation
increased substantially at several sites (asterisks) in cells
expressing Zif±M.CviPI and Zif±M.SssI versus mut Zif±
M.CviPI and M.SssI, respectively. Targeted modi®cation sites
(asterisks) are readily identi®able by normalizing to sites of
non-targeted methylation (®lled circles). In the case of Zif±
M.CviPI, which targets m5C more ef®ciently, 41, 12.4, 2.3 and
2.6% of GC sites 19, 41, 163 and 172, were methylated,
respectively. Since the methylation level at each of these sites
exceeds that at the normalization site 46 over a time course of
Zif±M.CviPI induction, different levels/duration of Zif±
M.CviPI expression do not affect the relative ef®ciency of
targeting m5C (Fig. 1C). The fold increases in m5C at each
targeted site in strains expressing Zif±M.CviPI versus mut
Zif±M.CviPI in three independent experiments are presented
in Figure 1D.
M.CviPI is targeted most ef®ciently to a site located 19 bp
from the ZBS (Fig. 1D), which correlates well with the
optimal distance of 10±40 bp observed when methylating
oligonucleotides with other DMTase fusion proteins in vitro
(37,38) and in yeast (40). This optimal distance for introdu-
cing m5C is likely related to the length and amino acid
sequence of the ¯exible peptide separating Zif268 and the
DMTase (38). However, targeting methylation distal to the
consensus ZBS (e.g. sites 163 and 183) is as or more ef®cient
than to some proximal sites (e.g. sites 41, 43 and 52) (Fig. 1A±
D). Preferential targeting of M.CviPI and M.SssI also occurs
distally, at sites 163±183 nt from the ZBS (Fig. 1A±D). A
single, DNA-bound monomer of Zif268 similarly targets both
DMTases close to (5±30 bp) and at a considerable distance
from (353 bp) a second consensus Zif268 site in YBR108W
(+2067 to +2075; Fig. 2A and B). For a third Zif268 binding
Figure 2. Zif268 targets M.CviPI and M.SssI to additional ZBS. (A) Determination of m5C levels. A region of YBR108W (+1564 to +2163) spanning a single
Zif268 site (+2067 to +2075; ®lled bar) was PCR ampli®ed from the same bisul®te-treated samples analyzed in Figure 1A. Sequencing ladders (A, T) are at
the right. Symbols are de®ned in the caption to Figure 1. (B) Scans of the phosphoimage in (A). The scanned lanes are indicated at the left. (C) Methylation
targeted to a third Zif268 site (®lled bar) near YOL019W (±397 to ±389). Only scans of the phosphoimage resulting from the bisul®te genomic sequencing of
the region from ±509 to +254 are shown.
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site (±397 to ±389 of YOL019W), two GC sites are protected
against methylation by Zif±M.CviPI bound at the ZBS, and
m5C is targeted to an additional GC site 39 bp from the ZBS
(Fig. 2C). In contrast, the relative levels of CG or GC site
methylation at the PHO5 promoter, which lacks Zif268 sites,
show no signi®cant differences between the wild-type Zif268
fusion and its respective free DMTase control (Fig. 3, compare
lanes 1 with 2 and 3 with 4). We conclude that the targeted
methylation is due to site-speci®c DNA binding by Zif268.
Targeting M.CviPI via phage display-selected Zip53
The engineered zinc-®nger protein Zip53, which speci®cally
binds to a p53 consensus site (5¢-GGGACATGT-3¢; hereafter
Zip53 binding site) (41), was previously fused to M.SssI and
used in vitro to target methylation next to its cognate binding
site in an oligonucleotide substrate (37). We tested if Zip53
could direct methylation by M.CviPI to regions containing a
single Zip53 site in vivo. As above, the Zip53±M.CviPI fusion
protein was integrated as a single copy at LYS2 and expressed
from the GAL1 promoter. First, we analyzed m5C levels near
the consensus Zip53 binding site located in the DED1 coding
Figure 3. Absence of site-selective methylation at unlinked loci. The PHO5
promoter (±1009 to ±205), lacking Zif268 sites, was PCR ampli®ed from
the same bisul®te-treated samples analyzed in Figures 1 and 2A to deter-
mine levels of m5C. The positions of the two known Pho4 transactivator
binding sites, UASp1 and UASp2 (open bars), localized to a histone-free,
DNase I-hypersensitive region and positioned nucleosome ±2 (partial
ellipse) (64), respectively, are indicated. GC (lanes 1 and 2) and CG (lanes
3 and 4) sites (®lled circles). Note that, relative to the mut Zif±M.CviPI
control (lane 1), the lower methylation frequencies in the Zif±M.CviPI
strain (lane 2) at each GC site is consistent with the conclusion that it has
reduced overall methylation activity. However, the similar ratios of site
intensities within lanes 1 and 2 (M.CviPI) as well as within lanes 3 and 4
(M.SssI) demonstrate that m5C accumulates independent of the Zif (or mut
Zif) fusion moiety.
Figure 4. The engineered zinc-®nger protein, Zip53, targets a DMTase to
DED1. (A) Determination of m5C levels at DED1 (+475 to +67). Targeted
methylation (asterisks), normalized to site 141 (arrow), is detected at GC
sites 30, 162 and 178 bp away from the Zip53 binding site (hatched bar) in
two Zip53±M.CviPI strains (lanes 2 and 3) that are representative of four
independent strains containing the integrated Zip53±M.CviPI fusion gene.
Filled circles indicate remaining CG and GC sites of non-targeted methyl-
ation (not selectively methylated) on expression of Zip53±M.CviPI. Lanes 1
and 4 contain bisul®te genomic sequencing results from the mut Zif±
M.CviPI strain and a Zip53±M.CviPI transformant that contains a non-func-
tional DMTase, respectively. Sequencing ladders (T, G, A) are at the right.
(B) Quantitative scans of the phosphoimage in (A). Symbols are de®ned as
in (A).
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sequence (+284 to +276; Fig. 4). As expected, since yeast do
not have endogenous cytosine DMTases, no modi®ed
cytosines are evident in a strain that does not contain a
functional copy of M.CviPI (Fig. 4A, lane 4). Normalizing to
site 141, relative to the `free' DMTase control (mut Zif±
M.CviPI), targeted methylation is detected 30 bp from the
DED1 consensus Zip53 site on expression of Zip53±M.CviPI
(Fig. 4A, compare lanes 2 and 3 with lane 1). Further, long-
range methylation at sites 162 and 178 bp from the consensus
ZBS is substantially enhanced. Lastly, there is reproducible,
low-level protection of a GC site located 3 bp from the ZBS,
indicative of Zip53 binding (Fig. 4A and B).
We also observed long-range targeting of m5C from a
second consensus Zip53 site located in the YLR016C coding
sequence (+298 to +306; Fig. 5A and B). Methylation was
enhanced 5.5-fold at site 184, and somewhat less, but
signi®cantly (~2.2-fold), at sites 157 and 190 in strains
expressing Zip53±M.CviPI relative to mut Zif±M.CviPI.
Protection against DNA methylation could not be observed
because no GC sites are adjacent to or within the Zip53
binding site. To examine the speci®city of the Zip53±DMTase
fusion protein, we analyzed m5C levels at the CAR1 locus
(Fig. 1), which contains a Zif268 site, but no Zip53 site
(Fig. 5C). In each lane of the gel in Figure 5C, little to no
change exists in the relative methylation levels of 13 GC sites
at CAR1. In particular, methylation at site 19 of the CAR1
region, which shows >20-fold enrichment following expres-
sion of Zif±M.CviPI (Fig. 1), is not increased in the presence
of Zip53±M.CviPI. This result demonstrates that Zip53
speci®cally binds its site, but not that of Zif268 (the two
binding sites have 22% identity). We conclude that, as for
Zif268, Zip53 is able to target M.CviPI and thereby signi®-
cantly increase cytosine methylation at select GC sites near
and distal to a cognate ZBS. The use of Zip53 to deliver m5C
selectively further demonstrates that zinc-®nger proteins
engineered to recognize pre-determined sequences can be
used to introduce de novo methylation essentially to any
region of interest.
DISCUSSION
In this report, we demonstrate the ability to target m5C in vivo
using two zinc-®nger proteins, Zif268 and its arti®cially
engineered derivative Zip53. First, signi®cant targeting of
m5C is observed at select sites both adjacent (5±52 bp) and
distal (>150 bp) to a cognate, consensus ZBS (Figs 1, 2, 4 and
5A and B), whereas DNA methylation is not enriched at
control loci lacking the ZBS (Figs 3 and 5C). Proximal and
distal targeting of m5C was also observed in our previous
studies using Pho4 as the DMTase targeting factor (40). The
reasons for selective targeting of m5C to some sites as opposed
to others in the same region are not currently understood. At
least locally, the length of the peptide linker separating the
DMTase and the targeting factor, the helical face of a
particular CG or GC site relative to the DNA-bound targeting
factor, and accessibility in chromatin each presumably
contribute to the preferential targeting. Secondly, since
DNA-bound factors impair access of DMTases to their target
sites (26±30,40), the protection against methylation of CG or
GC sites next to or within the ZBS provides further evidence
of speci®c ZBS binding by each zinc-®nger±DMTase fusion
Figure 5. Zip53-mediated targeting of m5C to YLR016C. (A) Determination
of m5C levels at YLR016C (+418 to +28). Targeted methylation (asterisks),
as normalized to site 40 (arrow), is detected at GC sites 157, 184 and 190 bp
away from the Zip53 site (hatched bar) in two independent transformants
(lanes 3 and 4) relative to mut Zif±M.CviPI (lanes 1 and 2). T, G and A
sequencing ladders are at the right. Non-targeted methylation (®lled circles).
The sample in lane 5 was obtained from a Zip53±M.CviPI transformant har-
boring a non-functional DMTase. (B) Quantitative scans of the phospho-
image in (A). (C) Determination of m5C levels at the CAR1 locus (+558 to
+159) that has a Zif268 binding site (®lled bar) but no consensus Zip53
binding site. The PCR products analyzed in lanes 1±4 were ampli®ed from
the bisul®te-treated genomic analyzed in lanes 1±4, respectively, in (A).
Lane 5 contains a sample from a parental strain that was not transformed
with M.CviPI. Non-speci®c primer extension pauses that do not correspond
to GC sites are marked with brackets. Symbols in (B) and (C) are as de®ned
in (A).
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protein. Taken together, in addition to demonstrating selective
enrichment of m5C near ZBS, TAGM provides a highly
sensitive means for detecting protein±DNA interactions (40).
The occurrence of targeted m5C beyond distances of 40 nt
suggests that two sites well separated in protein-free DNA are
juxtaposed by looping, nucleosomes or higher-order chroma-
tin structure (e.g. Fig. 2A, 353 bp away from the ZBS). While
it is formally possible that the occurrence of distal methylation
is due to binding at a secondary, non-consensus ZBS, we do
not believe this to be the case. First, no footprints are observed
near MTase target sites that are >150 bp from the primary
Zif268 binding site, despite the fact that high-af®nity sites
contain two GC sites. Secondly, within 50 bp of each long-
range targeted m5C site any potential ZBS has a minimum of
four to ®ve mismatches from consensus. Since two or more
base substitutions result in background levels of binding
(42,52±54), it is highly unlikely that any of these sites
constitute a signi®cant secondary ZBS. Thirdly, it is improb-
able that distal secondary ZFP binding sites would be present
at all ®ve loci that were analyzed. Finally, Dam MTase can
also be targeted at a distance (55,56).
The design of multiple zinc-®nger modules with desired
speci®cities is proving a versatile platform for targeting a
variety of protein moieties to accessible sites in vivo (57). For
instance, engineered zinc-®nger proteins have been fused to
the catalytic domain of R.FokI endonuclease to direct site-
speci®c double-stranded DNA cleavage, and hence homo-
logous recombination, of desired regions (58). Designed
zinc-®nger proteins have also been used to target the catalytic
domains of the histone methyltransferases G9A and
SUV39H1 (59) as well as the VP16 activation domain
(60±62), leading to repression and activation, respectively,
of expression of the endogenous human erythropoietin (EPO),
vascular endothelial growth factor A (VEGF-A) and other
mammalian genes (57). This technology has also recently
been extended to the regulation of gene expression in plants
(63).
The targeting of DMTases by zinc-®nger proteins selected
to bind speci®c ZBS could provide an additional way to down-
regulate the expression of desired genes. Moreover, since the
DNA methylation state of a given promoter is maintained
heritably through DNA replication by endogenous cellular
mechanisms, an initial targeting event may be suf®cient to
establish stable silencing of improperly expressed genes.
Therefore, heritable repression could also reduce the amount
of treatment necessary to establish the proper regulation of a
particular gene. In addition to providing a potentially powerful
therapeutic tool, methylation-mediated repression of speci®c-
ally targeted genes could yield an alternative to transgenic
knockouts for studying loss-of-function phenotypes. Silencing
genes through DNA methylation would be particularly
valuable in the case of essential genes where tissue-speci®c
knockouts of function are needed. Optimization of targeting
factor occupancy at regions of interest will likely increase the
ef®cacy of speci®c m5C targeting in vivo as well as minimize
non-targeted methylation. The experimental system used
herein provides a useful assay for pursuing such further
investigations. Finally, the ability to target m5C speci®cally
in vivo is likely to prove valuable in basic investigations of the
biological roles and mechanistic consequences of DNA
methylation.
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